InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.645 0.06 (3.79%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$323 Application for quotation of securities - RAC 11 Sep 2025 2:35PM $1.510 $1.645 risen by 8.94%
$323 Application for quotation of securities - RAC 2 Sep 2025 1:55PM $1.220 $1.645 risen by 34.84%
$323 First Hong Kong Site Activated for RC220 Trial 2 Sep 2025 9:21AM $1.255 $1.645 risen by 31.08%
$323 First Hong Kong Site Activated for RC220 Trial 2 Sep 2025 9:21AM $1.255 $1.645 risen by 31.08%
$323 Appendix 4G 26 Aug 2025 4:48PM $1.200 $1.645 risen by 37.08%
$323 Corporate Governance Statement 26 Aug 2025 4:47PM $1.200 $1.645 risen by 37.08%
$323 Appendix 4E & Annual Report 26 Aug 2025 4:45PM $1.200 $1.645 risen by 37.08%
$323 Phase 2 Bisantrene AML Trial Results Published 4 Aug 2025 1:57PM $1.155 $1.645 risen by 42.42%
$323 Notification regarding unquoted securities - RAC 24 Jul 2025 4:34PM $1.185 $1.645 risen by 38.82%
$323 June 2025 Quarterly Activity Report and Appendix 4C 23 Jul 2025 8:28AM $1.140 $1.645 risen by 44.30%
$323 Race Oncology Upcoming 2025 Investor Events 15 Jul 2025 1:29PM $1.155 $1.645 risen by 42.42%
$323 RC220 Human Ethics Approvals Received in Hong Kong 10 Jul 2025 9:07AM $1.170 $1.645 risen by 40.60%
$323 Application for quotation of securities - RAC 26 Jun 2025 1:49PM $1.240 $1.645 risen by 32.66%
$323 Application for quotation of securities - RAC 19 Jun 2025 2:35PM $1.355 $1.645 risen by 21.40%
$323 First Patient Safely Combine Dosed in Phase 1 RC220 Trial 19 Jun 2025 8:56AM $1.270 $1.645 risen by 29.53%
$323 Termination of City of Hope Global IP License 17 Jun 2025 8:57AM $1.130 $1.645 risen by 45.58%
$323 Application for quotation of securities - RAC 6 Jun 2025 11:54AM $1.180 $1.645 risen by 39.41%
$323 Notification of cessation of securities - RAC 3 Jun 2025 10:27AM $1.205 $1.645 risen by 36.51%
$323 Race Gold Coast Brisbane Investor Events 2 Jun 2025 12:14PM $1.258 $1.645 risen by 30.82%
$323 Application for quotation of securities - RAC 29 May 2025 4:11PM $1.340 $1.645 risen by 22.76%
$323 Application for quotation of securities - RAC 22 May 2025 11:14AM $1.390 $1.645 risen by 18.35%
$323 Application for quotation of securities - RAC 7 May 2025 11:09AM $1.200 $1.645 risen by 37.08%
$323 Notification of cessation of securities - RAC 6 May 2025 3:51PM $1.160 $1.645 risen by 41.81%
$323 Race Announces Key Senior Clinical Team Appointments 5 May 2025 8:57AM $1.210 $1.645 risen by 35.95%
$323 First Patient Dosed Safely in RC220 Phase 1 Trial 1 May 2025 8:57AM $1.045 $1.645 risen by 57.42%

151 - 175 of 1002 results

Page 7 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.